Geneuro SA (GNRO) - Total Assets
Based on the latest financial reports, Geneuro SA (GNRO) holds total assets worth €6.36 Million EUR (≈ $7.44 Million USD) as of December 2023. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Geneuro SA for net asset value and shareholders' equity analysis.
Geneuro SA - Total Assets Trend (2012–2023)
This chart illustrates how Geneuro SA's total assets have evolved over time, based on quarterly financial data.
Geneuro SA - Asset Composition Analysis
Current Asset Composition (December 2023)
Geneuro SA's total assets of €6.36 Million consist of 36.7% current assets and 63.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.83 Million | 28.7% |
| Accounts Receivable | €162.10K | 2.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €742.10K | 11.7% |
| Intangible Assets | €1.15 Million | 18.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how Geneuro SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GNRO market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Geneuro SA's current assets represent 36.7% of total assets in 2023, a decrease from 94.4% in 2012.
- Cash Position: Cash and equivalents constituted 28.7% of total assets in 2023, down from 73.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 17.0% in 2012.
- Asset Diversification: The largest asset category is cash and equivalents at 28.7% of total assets.
Geneuro SA Competitors by Total Assets
Key competitors of Geneuro SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merus BV
NASDAQ:MRUS
|
USA | $771.99 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Savara Inc
NASDAQ:SVRA
|
USA | $140.92 Million |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥2.96 Billion |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Geneuro SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.37 | 2.75 | 1.95 |
| Quick Ratio | 0.37 | 2.32 | 1.95 |
| Cash Ratio | 0.29 | 1.69 | 0.00 |
| Working Capital | €-3.92 Million | €5.78 Million | €6.06K |
Geneuro SA - Advanced Valuation Insights
This section examines the relationship between Geneuro SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.15 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -44.3% |
| Total Assets | €6.36 Million |
| Market Capitalization | $911.56K USD |
Valuation Analysis
Below Book Valuation: The market values Geneuro SA's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Geneuro SA's assets decreased by 44.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Geneuro SA (2012–2023)
The table below shows the annual total assets of Geneuro SA from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €6.36 Million ≈ $7.44 Million |
-44.29% |
| 2022-12-31 | €11.42 Million ≈ $13.35 Million |
-8.06% |
| 2021-12-31 | €12.42 Million ≈ $14.52 Million |
+19.02% |
| 2020-12-31 | €10.44 Million ≈ $12.20 Million |
+12.19% |
| 2019-12-31 | €9.30 Million ≈ $10.87 Million |
+66094.85% |
| 2018-12-31 | €14.05K ≈ $16.43K |
-53.73% |
| 2017-12-31 | €30.37K ≈ $35.50K |
-19.62% |
| 2016-12-31 | €37.78K ≈ $44.17K |
+81.96% |
| 2015-12-31 | €20.76K ≈ $24.27K |
-99.77% |
| 2014-12-31 | €9.06 Million ≈ $10.59 Million |
+115.83% |
| 2013-12-31 | €4.20 Million ≈ $4.91 Million |
-18.42% |
| 2012-12-31 | €5.14 Million ≈ $6.01 Million |
-- |
About Geneuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsy… Read more